Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series
Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NLM (Medline)
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |